MOC (Maintenance of Certification)

  2. Home
  3. Credit Type
  4. MOC (Maintenance of Certification)
  5. Format
Page 7 of 7
Results 451 - 501 of 501
No image set
UIP, IPF, NSIP, CHP: Making Sense of the Letters
t2diabetes-louise
Getting to Goal Can Be Difficult: Louise
t2diabetes-brian
Getting to Goal Can Be Difficult: Brian
IL-rheum-case3
Considering Biosimilars in Patients Failing their Initial Biologic
IL-rheum-case2
When to Switch? Biologically Experienced Patients with Spondyloarthritis
IL-rheum-case1
Innovator or Biosimilar for a Patient with Rheumatoid Arthritis
IL-gastro-case3
Ulcerative Colitis: What Can You Expect When a Patient is Switched to a Biosimilar?
IL-gastro-case2
Biosimilars in Patients with Crohn’s Disease Failing an Initial Biologic
IL-gastro-case1
Innovator or Biosimilar for a Patient with Ulcerative Colitis?
IL-derm-case3
Switching Between Biologics: Is a Biosimilar an Option?
IL-derm-case2
When to Switch? Biologically Experienced Psoriasis Patients
IL-derm-case1
Innovator or Biosimilar for a Patient with Psoriasis
IL-fund-case4
Interchangeability and Pharmacy-Level Substitution
IL-fund-case3
FDA Criteria: Biosimilar Approval, Manufacturing, & Naming
IL-fund-case2
What is the Difference Between a Biosimilar and a Generic?
IL-fund-case1
What is a Biologic?
No image set
New Strides in EGFR Inhibition for Non–Small Cell Lung Cancer
No image set
Pete - Work-Up of a Patient with Right Upper Lobe Mass and Metastases
No image set
Carl - High Suspicion of Lung Cancer: Setting the Stage with a Good Biopsy
biosims-full
Sorting it Out: Biologics, Biosimilars, Small Molecule Drugs, and Generics
biosims-green5
Are You Ready to Use Biosimilars in Your Practice?
biosims-full3
Health Care Providers’ Perspectives on Biosimilars: Based in Fact or Not?
biosims-green3
Pharmacovigilance and Biosimilars: Any Special Considerations?
biosims-full5
Interchangeability and Biosimilars: What will this Mean for Clinical Practice?
biosims-green8
Can a Biosimilar be Used for the Same Indications Approved for the Reference Biologic?
biosims-full7
Biosimilars: As Safe and Effective as the Reference Product?
biosims-green
Drift and the Manufacturing of Biologics: What is it and Does it Matter?
No image set
Radiologic Features of IPF
No image set
Gwen: A lawyer with a history of MI has a dry cough and trouble with stairs
No image set
Elizabeth: Loves the outdoors but bothered by persistent cough and GERD
No image set
Toni: Too tired to continue teaching and experiencing painful heartburn
No image set
Individualizing Patient Education in Treatment Choice: Practical Strategies
lgmw-05
A 30 y/o Female w/2-year History of Shoulder Weakness and Elevated AST and ALT
lgmw-04
32 y/o Male w/Progressive Weakness, Dilated Cardiomyopathy & Respiratory...
lgmw-03
A 60 y/o Male w/4-year History Of Shoulder Weakness
biosims-full8
Biosimilars in Clinical Practice: Interchangeability and Extrapolation
No image set
Individualizing Patient Education in Treatment Choice: Practical Strategies
No image set
Addressing Common Barriers to Adherence
9529-00028
Approach to Genetic Testing in Myopathies
9529-00014
Molecular Diagnosis of Limb-Girdle Muscle Weakness
No image set
Discovering New Drugs for IPF
No image set
Biomarkers for IPF
No image set
New Trends in IPF
No image set
New Trends in IPF
No image set
Treatment Dilemmas Case Study: Harrison
No image set
A New Era in IPF: Trials and Treatments
No image set
Highlights from ATS 2014: Discussions on Clinical Trial Data
No image set
Highlights from ATS 2014: Update on Predicting Clinical Progression
No image set
Highlights from ATS 2014: Top Line Clinical Trial Results - ASCEND, INPULSIS, and PANTHER
No image set
Exciting IPF Developments from 2015 ERS
No image set
Exciting Developments from 2015 CHEST
Page 7 of 7

Search